- Home
- ALXO
as 11-25-2025 2:54pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 79.7M | IPO Year: | 2020 |
| Target Price: | $3.30 | AVG Volume (30 days): | 356.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $2.27 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Sep 17 '25 | Buy | $1.08 | 71,163 | $76,891.62 | 305,121 | |
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Sep 16 '25 | Buy | $1.07 | 21,070 | $22,460.62 | 305,121 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
ALX Oncology to Present at Upcoming Investor Conferences
GuruFocus.com
18 days ago
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ...
GlobeNewswire
a month ago
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
GlobeNewswire
a month ago
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Zacks
a month ago
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
GlobeNewswire
2 months ago
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire
2 months ago
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
GlobeNewswire
6 months ago
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
Compare ALXO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.